acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)
Jump to navigation
Jump to search
Etiology
- many cases are preceded by a myelodysplastic syndrome (MDS) or a myelodysplastic/myeloproliferative neoplasm
Genetics
- most cases of AML-MRC associated with genetic aberrations, particularly -5/del(5q), -7/del(7q), &/or complex karyotypes
Management
- cytarabine/daunorubicin (Vyxeos) FDA-approved Aug 2017
More general terms
Additional terms
References
- ↑ Vardiman J, Reichard K. Acute Myeloid Leukemia With Myelodysplasia-Related Changes. Am J Clin Pathol. 2015 Jul;144(1):29-43. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26071460
- ↑ Bankhead C. FDA Approves Fixed Chemo Combo for AML Subtypes. First approval for treatment- and myelodysplasia-related AML. MedPage Today. August 03, 2017 https://www.medpagetoday.com/HematologyOncology/Leukemia/67045